Preclinical Data Supporting Antitumor Activity of PD-1 BlockadeCurran, Michael, A., PhDThe Cancer Journal: January/February 2018 - Volume 24 - Issue 1 - p 2–6 doi: 10.1097/PPO.0000000000000298 Review Articles Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Antibodies that block the PD-1 coinhibitory receptor on T cells or its primary ligand, PD-L1, have demonstrated unprecedented efficacy across a diverse array of both solid and hematologic malignancies in the clinic. These advances were built on a foundation of murine preclinical tumor model studies, which both demonstrated the therapeutic potential of PD-1/PD-L1 antibody blockade and also provided critical insights into the cellular and molecular processes underlying their capacity to elicit immune-mediated tumor regressions. As the field of immunotherapy moves toward higher-order combinations of agents, effective utilization of murine tumor models to optimize the composition of PD-1 antibody combination therapies, as well as their dosing and scheduling, will be essential for effective clinical translation. Novel murine models bearing human tumor xenografts and engrafted human immune systems may help close the gap between preclinical and clinical immunobiology. From the Department of Immunology, The University of Texas MD Anderson Cancer Center; and MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX. The author has disclosed that he has no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Michael A. Curran, Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 901, Houston, TX, 77054. E-mail: email@example.com. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.